| Primary | Feasibility of Peginterferon Alfa-2a Administration by Autoinjector | The feasibility of PEG-INF administration by AI was assessed by Injection Method Observational Survey questions, based on following pre-defined questions using a "Yes" or "No" response: 1) Did the participant exhibit any nervousness prior to the injection? 2) Did the participant exhibit any difficulty initiating the injection? 3) Did the participant appear confident performing the injection? 4) Did the participant follow the instructions for performing the injection without the need for additional instructions or guidance? 5) Did the participant experience any technical problems with the device or syringe during the injection? 6) Did the participant withdraw the device/syringe before the injection was complete? 7) Did the participant exhibit any visible pain or physical discomfort? 8) Did the participant appear to be satisfied using the device or syringe? 9) Did the participant exhibit any frustration using the syringe or device? | The intent-to-treat (ITT) population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 2 (Day 8 ± 2 days), Week 3 (Day 15 ± 2 days), Week 4 (Day 22 ± 2 days), Week 5 (Day 29 ± 2 days), Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
| | | Title | Denominators | Categories |
|---|
| Injection 1, Nervousness, Yes | | | | Injection 1, Nervousness, No | | |
| |
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Hemoglobin, Albumin and Total Protein | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for hemoglobin was 110-200 (gram per liter [g/L]), albumin was 30.0-n.d g/L, and total protein was 55-87 g/L. The clinical relevant change (decrease/ increase) for hemoglobin was (15%, 15%), albumin was (20%, n.d) and total protein was (20%, 20%) respectively. | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
|
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Hematocrit | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for hematocrit was 0.31-0.56 fraction. The clinical relevant change (decrease/ increase) for hematocrit was (15%, 15%). | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
|
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Platelet, White Blood Cell (WBC), Basophil, Eosinophil, Lymphocyte, Monocyte and Neutrophil | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for Platelets was 100-550 (10*9/L), for WBC was 3.0-18.0 (10*9/L), for Basophils was 0.00-0.40 (10*9/L), for Eosinophil was 0.00-0.90 (10*9/L), for Lymphocytes was 0.70-7.60 (10*9/L), Monocyte was 0.00-1.70 (10*9/L), and Neutrophil 1.50-9.25 (10*9/L). The clinical relevant change (decrease/increase) for platelet was (30%, 50%), WBC was (30%, 30%), Basophil was (n.d, 100%), Eosinophil was (n.d, 100%), Lymphocyte was (30%, 30%), Monocyte was (n.d, 100%) and Neutrophil was (20%, 20%) respectively. | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe |
|
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Right Blood Cell (RBC) | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for RBC was 3.80-6.10 (10*12/L). The clinical relevant change (decrease/ increase) for RBC was (15%, 15%). | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
|
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Prothrombin Time (PT) International Normalized Ratio (INR) | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for PT-INR was n.d.-2.00. The clinical relevant change (decrease/ increase) for PT-INR was (n.d, 30%). | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
|
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic-Pyruvic Transaminase (SGPT), and Alkaline Phosphatase | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for SGOT was 0-80 (Units Per Litre [U/L]), SGPT was 0-110 U/L, and alkaline phosphatase was 0-220 U/L. The clinical relevant change (decrease/ increase) for SGOT was (n.d, 50%), SGPT was (n.d, 50%), and ALP was (n.d, 50%) respectively. | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
|
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Blood Urea Nitrogen (BUN), Chloride, Potassium, Sodium, Calcium, Glucose | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for BUN was 0.0-14.3 (millimoles per Liter [mmol/L]), Chloride was 95-115 (mmol/L), Potassium was 2.9-5.8 (mmol/L), Sodium was 130-150 (mmol/L), Calcium was 2.00-2.90 (mmol/L), and Glucose was 2.80-11.10 (mmol/L). The clinical relevant change (decrease/ increase) for BUN was (n.d, 50%), Chloride was (7%, 7%), Potassium was (20%, 20%), Sodium was (7%, 7%), Calcium was (10%, 10%), and Glucose was (75%, 75%) respectively. | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | |
|
| Secondary | Number of Participants With Marked Laboratory Abnormalities in Creatinine | A marked abnormality was defined as a test result which was outside of the marked abnormality range, and which represented a clinically relevant change from baseline of at least the designated amount. The marked reference range for Creatinine was 0- 154 (micromoles/liter [umol/L]). The clinical relevant change (decrease/ increase) for Creatinine was (n.d, 50%). | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
|
| Secondary | Number of Participants With Abnormalities in Pulse Rate, Temperature, and Blood Pressure | The pulse rate, temperature and blood pressure was assessed during a physical examination. Pulse rate was assessed in beats per minute (bpm), temperature was assessed in degree Celsius (°С), and blood pressure was assessed in millimeters of mercury (mmHg). Vital signs were taken while the participant was supine. | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 2 (Day 8 ± 2 days), Week 3 (Day 15 ± 2 days), Week 4 (Day 22 ± 2 days), Week 5 (Day 29 ± 2 days), Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
|
| Secondary | Number of Participants With Abnormalities in Electrocardiograms | A 12-lead ECG was recorded after the participant had been in a semi-supine position for at least 10 minutes. Any clinically significant abnormalities noted on an ECG after the first dose of study drug were captured as AEs | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Week 1, Day 1 (Baseline), Week 4 (Day 22 ± 2 days), and Week 6 (Day 36 ± 2 days) | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
| |
| Secondary | Number of Participants With Adverse Events (AE) | An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. | The ITT population included all participants who received at least one injection | Posted | | Number | | participants | | Upto Day 36 | | | | ID | Title | Description |
|---|
| OG000 | Autoinjector | The AI group includes results from Weeks 1-3 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) and results from Weeks 4-6 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6) | | OG001 | Pre-filled Syringe | The PFS group includes results from Weeks 1-3 for participants in Treatment Group B (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by PFS for the Weeks 1-3, followed by AI for Weeks 4-6)and results from Weeks 4-6 for participants in Treatment Group A (Participants received 180 mcg/0.5 mL PEG-IFN subcutaneously once a week by AI for Weeks 1-3, followed by PFS for Weeks 4-6) |
| |